bpc-157 tga approval The TGA has escalated its focus on unapproved peptide products amid rising Unapproved peptides seized as TGA

If your pilot study indicates a particular 5-Amino-1MQ dosage is yielding suboptimal results, systematically adjust and re-evaluate

The only data we have on BPC-157 being used in humans comes from a handful of small clinical trials, as such, finding a proper dosage can be difficult

Current medical research supports the concurrent use of these supplements under proper medical advice

Immunosuppressive drug therapy and bone marrow transplants are another option

Audit patterns that draw OIG attention A few habits put dysphagia claims on an auditor's radar: Using R13.10 on every claim and never updating to a phase code after a study confirms one